Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test

This document is a Response to Comments regarding the MolDX Envisia (Veracyte) diagnostic test for idiopathic pulmonary fibrosis and documents procedural dates (comment period 2018-10-04 to 2018-12-14; notice period 2019-04-11 to 2019-05-26) and finalization of LCD DL37887 on 2019-05-27. The provided text contains no clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits; review of LCD DL37887 is required to extract specific coverage criteria.